A phase II clinical trial evaluated the immune and clinical outcome of an HLA-A*0201-restricted WT1 epitope peptide vaccine administered with granulocyte colony-stimulating factor (G-CSF) in 17 refractory AML patients [15]. The gene discussed is WT1; the disease is acute myeloid leukemia.